Total Payments
$2,023
2024 Payments
$316.72
Companies
20
Transactions
66
Medicare Patients
10,057
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$1,996 (98.7%)
Education$26.64 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,996 | 64 | 98.7% |
| Education | $26.64 | 2 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $601.51 | 29 | $0 (2024) |
| PFIZER INC. | $248.76 | 3 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $246.77 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $203.74 | 8 | $0 (2024) |
| Boston Scientific Corporation | $188.05 | 3 | $0 (2024) |
| Amarin Pharma Inc. | $141.89 | 2 | $0 (2019) |
| GE HealthCare | $48.00 | 1 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $44.96 | 2 | $0 (2022) |
| Kiniksa Pharmaceuticals International, plc | $44.35 | 1 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $39.92 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $316.72 | 13 | Novartis Pharmaceuticals Corporation ($92.33) |
| 2023 | $215.05 | 8 | Novartis Pharmaceuticals Corporation ($65.75) |
| 2022 | $245.38 | 13 | Amgen Inc. ($132.01) |
| 2021 | $80.36 | 4 | Amgen Inc. ($55.82) |
| 2020 | $62.96 | 3 | Amgen Inc. ($42.07) |
| 2019 | $640.81 | 16 | Amgen Inc. ($191.98) |
| 2018 | $234.79 | 5 | PFIZER INC. ($122.49) |
| 2017 | $226.49 | 4 | AstraZeneca Pharmaceuticals LP ($212.62) |
All Payment Transactions
66 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $28.92 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 08/15/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Cardiology | ||||||
| 07/29/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $44.35 | General |
| Category: Not Applicable | ||||||
| 05/07/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/05/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Education | In-kind items and services | $20.74 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: DIABETES | ||||||
| 02/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $28.47 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/27/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/21/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $17.77 | General |
| Category: Coronary | ||||||
| 02/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/30/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $27.65 | General |
| Category: Cardiology | ||||||
| 01/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/05/2024 | Boston Scientific Corporation | Ranger (Device) | Food and Beverage | In-kind items and services | $29.73 | General |
| Category: Ranger_PI | ||||||
| 12/13/2023 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 12/05/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: Cardiology | ||||||
| 11/21/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $32.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/29/2023 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Cardiology | ||||||
| 06/06/2023 | PFIZER INC. | ELIQUIS (Drug), COMIRNATY | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 05/16/2023 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: Cardiology | ||||||
| 03/07/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $33.37 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/23/2023 | Boston Scientific Corporation | EkoSonic (Device) | Food and Beverage | In-kind items and services | $35.24 | General |
| Category: EkoSonic_PI | ||||||
| 12/01/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Cardiology | ||||||
| 10/28/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/23/2022 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: Cardiology | ||||||
| 06/22/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 2,621 | 3,876 | $1.6M | $373,578 |
| 2022 | 23 | 2,513 | 4,209 | $1.5M | $373,598 |
| 2021 | 26 | 2,613 | 4,331 | $1.6M | $418,751 |
| 2020 | 26 | 2,310 | 3,701 | $1.2M | $307,946 |
Total Patients
10,057
Total Services
16,117
Medicare Billing
$1.5M
Procedure Codes
97
All Medicare Procedures & Services
97 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 204 | 761 | $268,465 | $77,371 | 28.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 311 | 442 | $261,985 | $66,590 | 25.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 444 | 584 | $248,460 | $57,899 | 23.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 258 | 274 | $252,916 | $48,044 | 19.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 60 | 207 | $151,472 | $37,360 | 24.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 154 | 167 | $103,506 | $24,463 | 23.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 116 | 116 | $83,969 | $20,604 | 24.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 72 | 140 | $33,610 | $9,498 | 28.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 513 | 628 | $46,520 | $7,583 | 16.3% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 35 | 35 | $32,653 | $7,430 | 22.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 42 | 43 | $18,279 | $4,790 | 26.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $16,554 | $3,806 | 23.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 156 | 205 | $3,256 | $1,722 | 52.9% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 35 | 35 | $9,079 | $1,644 | 18.1% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 38 | 40 | $3,645 | $876.67 | 24.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 13 | 13 | $5,539 | $788.62 | 14.2% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Office | 2023 | 35 | 35 | $9,380 | $780.15 | 8.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 13 | 22 | $2,303 | $611.31 | 26.5% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 29 | 30 | $2,510 | $602.40 | 24.0% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 11 | 17 | $2,964 | $533.87 | 18.0% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 29 | 29 | $1,599 | $320.56 | 20.0% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 23 | 23 | $1,284 | $261.16 | 20.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 194 | 1,045 | $344,855 | $90,472 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 494 | 805 | $345,319 | $83,628 | 24.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 242 | 254 | $216,500 | $44,446 | 20.5% |
About Dr. Michael Share, M.D
Dr. Michael Share, M.D is a Cardiovascular Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/20/2012. The National Provider Identifier (NPI) number assigned to this provider is 1528333879.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Share, M.D has received a total of $2,023 in payments from pharmaceutical and medical device companies, with $316.72 received in 2024. These payments were reported across 66 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($1,996).
As a Medicare-enrolled provider, Share has provided services to 10,057 Medicare beneficiaries, totaling 16,117 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 97 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Internal Medicine
- Location Los Angeles, CA
- Active Since 03/20/2012
- Last Updated 04/24/2019
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1528333879
Products in Payments
- Repatha (Biological) $435.67
- ELIQUIS (Drug) $262.47
- BRILINTA (Drug) $212.62
- Corlanor (Drug) $165.84
- Vascepa (Drug) $141.89
- LEQVIO (Drug) $137.16
- WATCHMAN (Device) $123.08
- ENTRESTO (Drug) $66.58
- VSCAN (Device) $48.00
- XARELTO (Drug) $44.96
- Arcalyst (Drug) $44.35
- OPSUMIT (Drug) $39.92
- EkoSonic (Device) $35.24
- WAINUA (Drug) $34.15
- Inpefa (Drug) $29.87
- Ranger (Device) $29.73
- EVKEEZA (Biological) $28.92
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (Device) $24.54
- FUROSCIX (Drug) $23.83
- JARDIANCE (Drug) $21.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Los Angeles
Dr. Leslie Saxon, M.d, M.D
Cardiovascular Disease — Payments: $1.6M
Cardiovascular Disease $1.6M
Dr. Cathleen Bairey Merz, M.d, M.D
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Ramin Ebrahimi, Md, MD
Cardiovascular Disease — Payments: $879,009
Cardiovascular Disease $879,009
Karol Watson, Md, MD
Cardiovascular Disease — Payments: $707,428
Cardiovascular Disease $707,428
Alexander Ford, Md, MD
Cardiovascular Disease — Payments: $563,203
Cardiovascular Disease $563,203
Rahul Doshi, M.d, M.D
Cardiovascular Disease — Payments: $479,484
Cardiovascular Disease $479,484